immunotoxin

(redirected from Immunotoxins)
Also found in: Dictionary, Encyclopedia.

immunotoxin

/im·mu·no·tox·in/ (im´u-no-tok″sin) any antitoxin.

immunotoxin

(ĭm′yə-nō-tŏk′sĭn, ĭ-myo͞o′-)
n.
A hybrid molecule formed by binding a toxin to a monoclonal antibody, used to destroy tumor cells.

immunotoxin (IT)

[-tok′sin]
a toxin that is attached to a monoclonal antibody and used to destroy a specific type of target cell. An example is the plant toxin ricin, which inhibits protein synthesis in tumor cells that are recognized by the antibodies to which ricin is attached.

immunotoxin

an antibody attached to a specific toxic agent that is used to destroy specific cancer cells. Although experimental at present, these so-called ‘magic bullets’ hold out great hope as a new form of cancer CHEMOTHERAPY.

immunotoxin

an antitoxin.
References in periodicals archive ?
Saporin, the killer that scientists have employed in many immunotoxins as well, interferes with ribosomes, which are protein-synthesizing factories inside all cells.
The anti-CD22 immunotoxins GCR-3888 and GCR-8015 comprise a dsFv that targets the CD22 receptor, fused with a specifically engineered toxin molecule that minimizes non-targeted toxicity, resulting in a highly specific, highly potent therapeutic molecule.
Vitetta and her colleagues encountered vascular leak syndrome when they began testing immunotoxins in cancer patients.
Immunotoxins are drugs created by linking an antibody to a portion of bacterial or plant toxin to destroy cells expressing the molecule to which the antibody binds.
5 Will Next-Generation Immunotoxins Impact the Market to 2024?
The present invention also provides a method for decreasing the number of immune cells in an individual using the heat shock protein immunotoxins of the present invention.
A number of immunotoxins currently in clinical trials are antibody-based reagents.
In a chapter of the text that reviews immunotoxins, Susanna Rybak, Ph.
Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
His current research continues to focus on the use of immunotoxins to treat cancer.
For example, functional monoclonal antibodies comprising a heavy chain and a light chain of an immunoglobulin, and functional immunotoxins comprising an antibody domain and an oxidase toxin may be produced using the Yeast expression system of the present invention.